Upper extremity versus lower extremity for secondary access during transcatheter aortic valve implantation: rationale and design of the randomised TAVI XS trial

• Published in: Netherlands heart journal 2024-08, Vol.32 (7-8), p.270-275
• Main Authors: Rooijakkers, Maxim J. P., Versteeg, Geert A. A., Hemelrijk, Kimberley I., Aarts, Hugo M., Overduin, Daniël C., van Ginkel, Dirk-Jan, Vlaar, Pieter J., van Wely, Marleen H., van Nunen, Lokien X., van Geuns, Robert Jan, van Garsse, Leen A. F. M., Geuzebroek, Guillaume S. C., Verkroost, Michel W. A., Rodwell, Laura, Heijmen, Robin H., Tonino, Pim A. L., ten Berg, Jurrien M., Delewi, Ronak, van Royen, Niels
• Format: Article
• Language: English
• Subjects: Cardiology; Consortia; Hospitals; Medical Education; Medicine; Medicine & Public Health; Mortality; Original Article – Study Design Article; Pacemakers; Patients; Ultrasonic imaging; Veins & arteries; Venous access
• ISSN: 1568-5888; 1876-6250
• DOI: 10.1007/s12471-024-01869-5

Background During transcatheter aortic valve implantation (TAVI), secondary access is required for angiographic guidance and temporary pacing. The most commonly used secondary access sites are the femoral artery (angiographic guidance) and the femoral vein (temporary pacing). An upper extremity approach using the radial artery and an upper arm vein instead of the lower extremity approach using the femoral artery and femoral vein may reduce clinically relevant secondary access site-related bleeding complications, but robust evidence is lacking. Trial design The TAVI XS trial is a multicentre, randomised, open-label clinical trial with blinded evaluation of endpoints. A total of 238 patients undergoing transfemoral TAVI will be included. The primary endpoint is the incidence of clinically relevant bleeding (i.e. Bleeding Academic Research Consortium (BARC) type 2, 3 or 5 bleeding) of the randomised secondary access site (either diagnostic or pacemaker access, or both) within 30 days after TAVI. Secondary endpoints include time to mobilisation after TAVI, duration of hospitalisation, any BARC type 2, 3 or 5 bleeding, and early safety at 30 days according to Valve Academic Research Consortium‑3 criteria. Conclusion The TAVI XS trial is the first randomised trial comparing an upper extremity approach to a lower extremity approach with regard to clinically relevant secondary access site-related bleeding complications. The results of this trial will provide important insights into the safety and efficacy of an upper extremity approach in patients undergoing transfemoral TAVI.